Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

NCT04996758 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: Toripalimab and Anlotinib

Sponsor

Sun Yat-sen University